Scholarlink

Background <p>Chemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment.</p> Case presentation <p>This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion.</p> Discussion <p>This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NSTEMI and supraventricular tachycardia post-chemotherapy: a rare cardiotoxic complication

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • Eilham Elias Jobir,
  • Merahi Kefyalew Merahi,
  • Kefelegn Negalign Mekuria,
  • Matyas Wondwossen Elssa,
  • Yidnekachew Asrat Birhan,
  • Mesfin Ayalew Tsegaye

摘要

Background

Chemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment.

Case presentation

This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion.

Discussion

This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.